We administer a vector containing cancer-suppressing genes or a vector incorporating siRNA to inhibit cancer-proliferation genes (gene therapy proteins) via intravenous drip every 1 to 4 weeks. This can be performed concurrently with standard treatments such as surgery, chemotherapy, and radiation therapy.